Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
remibrutinib - BTK inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
NCT04109313 (CLOU064A2201E1)
Chronic spontaneous urticaria (CSU)
Phase 2
250
Arms Intervention
Long-term safety and tolerability
Selected dose of LOU064 taken orally twice a day (morning and evening) from day
1 to week 52
Patients with CSU who have participated in preceding studies with LOU064
Target Patients
Read-out Milestone(s)
2022
Publication
TBD
91 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation